Incyte consensus picture on Wall Street, shares trade steadily on NASDAQ
Published on 06/30/2026 at 10:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 10:07.
Incyte (US45337C1027) sits on NASDAQ in the US biotech segment. The company is covered by a range of Wall Street houses that publish earnings estimates, ratings and price targets for the INCY shares.
What analysts broadly say
Analysts on Wall Street typically classify Incyte within the mid-cap biotechnology peer group next to companies such as Vertex Pharmaceuticals and Regeneron Pharmaceuticals. Publicly available consensus data usually aggregates ratings from banks, target prices and earnings expectations.
In this framework, many brokers assign a mix of Buy, Hold and occasionally Sell ratings to the INCY shares based on their view of the pipeline, established products and cash generation. The average target price in recent consensus snapshots often implies limited upside or downside versus the prevailing market price.
How the consensus is built
Consensus figures for Incyte are compiled from individual research reports that forecast revenue, operating margin and earnings per share over the coming years. These reports also weigh clinical trial risk, patent duration and competitive dynamics in oncology and immunology.
Large houses such as Goldman Sachs, Morgan Stanley or JPMorgan usually feed into these aggregates with their own detailed models. Smaller specialist biotech boutiques add further views, occasionally focusing on specific projects in myelofibrosis or graft-versus-host disease.
Further news and data on the Incyte shares
Background articles, price data and future updates on the Incyte stock are available in the dedicated topic section and via the company’s investor relations page.
The product behind the stock
Incyte’s best-known product is Jakafi, a JAK inhibitor used in the United States for myelofibrosis and polycythemia vera. The company also markets ruxolitinib cream for atopic dermatitis and vitiligo, and develops additional oncology and immunology therapies.
Where the Incyte shares trade
The Incyte shares (US45337C1027) trade on NASDAQ in US dollars; the latest verifiable price and exact as-of time should be taken from a current exchange or quote service before any investment decision.
Key data on the Incyte shares
- Company: Incyte Corporation
- ISIN: US45337C1027
- WKN: 896133
- Ticker: INCY
- Trading venue: NASDAQ
- Price (as of 2026-06-30, 10:07): latest price in USD, check live quote
- Market cap: latest market capitalization in USD (as of 2026-06-30)
- Sector / industry: Biotechnology / Pharmaceuticals
- Index membership: NASDAQ indices, including biotech benchmarks where applicable
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should obtain up-to-date price data and consult professional advice before making decisions.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
